{"prompt": "[\"associated with events that pose a threat to a patient's life or functioning. Seriousness\", '(not severity) serves as a guide for defining regulatory reporting obligations.', '9.2 Time Period and Frequency for Event Assessment and Follow-Up', 'For the purposes of this study, the period of observation extends from the time the', 'patient gives his study-specific informed consent until the end of study procedures are', 'completed.', 'If the investigator detects an SAE in a study patient after the end of the period of', 'observation and considers the event possibly related to prior study treatment, he or she', 'should contact the sponsor to determine how the AE should be documented and', 'reported.', 'All AEs must be reported in detail on the appropriate page in the eCRF and followed to', 'satisfactory resolution, until the investigator deems the event to be chronic or not', 'clinically significant, or until the patient is considered to be stable.', 'A follow-up telephone call will be performed for those patients with an ongoing AE which', 'the investigator believes to be not related to study treatment administration. A follow-up', 'visit to the study site may occur for those patients with an ongoing AE which the', 'investigator believes to be possibly related to study treatment administration.', 'All AEs must be reported in detail on the appropriate page in the eCRF and followed', 'until they are resolved or stable, or judged by the investigator to be not clinically', 'significant.', '9.3 Characteristics of an Adverse Event', '9.3.1 Relationship to Study Intervention', 'By definition, any AE that starts before the first dose of study treatment administration is', 'considered to be \"unrelated.\"', 'The investigator will assess the causality/relationship between the study treatment and', 'the AE according to Appendix A (Schedule of Events). One of the following categories', 'should be selected based on medical judgment, considering the following definitions', 'and all contributing factors.', 'Intra-Cellular Therapies, Inc. Confidential', '47 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Table 9-1', 'Causality Categories', 'Category', 'Definition', 'Definitely related', 'A clinical event, including laboratory test abnormality, occurs in a', 'plausible time relationship to treatment administration, and which', 'concurrent disease or other drugs or chemicals cannot explain. The', 'response to withdrawal of the treatment (dechallenge\u00b9) should be', 'clinically plausible. The event must be definitive pharmacologically or', 'phenomenologically, using a satisfactory rechallenge\u00b2 procedure if', 'necessary.', 'Probably related', 'A clinical event, including laboratory test abnormality, with a reasonable', 'time sequence to administration of the treatment, unlikely to be', 'attributed to concurrent disease or other drugs or chemicals, and which', 'follows a clinically reasonable response on withdrawal (dechallenge).', 'Rechallenge information is not required to fulfill this definition.', 'Possibly related', 'A clinical event, including laboratory test abnormality, with a reasonable', 'possibility that the adverse event may have been caused by the', 'treatment. Information on treatment withdrawal may be lacking or', 'unclear.', 'Unlikely to be', 'A clinical event, including laboratory test abnormality, with a temporal', 'related', 'relationship to treatment administration which makes a causal', 'relationship improbable, and in which other drugs, chemicals or', 'underlying disease provide plausible explanations.', 'Unrelated', 'A clinical event, including laboratory test abnormality, with little or no', 'temporal relationship with treatment administration. May have negative', 'dechallenge and rechallenge information. Typically, explained by', 'extraneous factors (e.g., concomitant disease, environmental factors, or', 'other drugs or chemicals).', '1 Dechallenge is when a drug suspected of causing an adverse event (AE) is discontinued. If the', 'symptoms of the AE disappear partially or completely, within a reasonable time from drug discontinuation,', 'this is termed a positive dechallenge. If the symptoms continue despite withdrawal of the drug, this is', 'termed a negative dechallenge. Note that there are exceptions when an AE does not disappear upon', 'discontinuation of the drug, yet drug-relatedness clearly exists (e.g., bone marrow suppression, fixed drug', 'eruptions, tardive dyskinesia).', '2 Rechallenge is when a drug suspected of causing an AE in a specific patient in the past is', 'readministered to that patient. If the AE recurs upon exposure, this is termed a positive rechallenge. If', 'the AE does not recur, this is termed a negative rechallenge.', '9.3.2', 'Expectedness of SAEs', 'The sponsor or designee will be responsible for determining whether an SAE is', 'expected or unexpected. An adverse event will be considered unexpected if the nature,', 'Intra-Cellular Therapies, Inc. Confidential', '48 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}